There is a category of drug approval that makes a cardiologist put down the sandwich, and Thursday produced one. The FDA approved Merck’s (MRK) Lipfendra — the first oral PCSK9 inhibitor to reach the market, a pill that does what until now required a needle.
The number that matters: Lipfendra cuts bad cholesterol by roughly 60%, versus the 20–30% you get from statins alone. The Street has penciled in $5 billion-plus in peak annual sales. Until now, the PCSK9 drugs that deliver that kind of reduction — Amgen’s (AMGN) Repatha, Regeneron’s (REGN) Praluent — came as injectables, which is a hard sell to a patient who would rather do almost anything than give themselves a shot every two weeks.
Merck’s bet is convenience. Price it competitively with the injectables, and let the pill win on the one dimension patients actually feel. Your arteries, as ever, remain one of the great addressable markets.
Here is the part worth saying plainly for the book: a category this large does not crown one winner — it feeds three. The lipid business has been minting money since the first statin came off the line decades ago. Competition on efficacy and price is good for patients; it is not, by itself, a reason to rotate the whole healthcare sleeve toward one name.
MRK stays reinforced — but for the right reason. Not because one pill makes the company; big pharma is a portfolio business, and Merck’s pipeline is deep. Because a first-in-class oral in a validated category is low-risk, high-durability revenue. Amgen (AMGN) and Regeneron (REGN) stay held on their own merits — the lipid market is large enough for all three. We treat the Lipfendra approval as validation of the category, not a rotation bet. Healthcare stays a core defensive sleeve.